King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

By Michael Gibney • Jan. 25, 2024

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

By Michael Gibney • Jan. 24, 2024

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

Breast cancer tops list of most studied diseases

The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

By Kelly Bilodeau • Jan. 24, 2024

The hunt for an elusive universal coronavirus vaccine

A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

By Alexandra Pecci • Jan. 22, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

How to make 2024 a banner year for biopharma, despite the headwinds

Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

By Michael Gibney • Jan. 18, 2024

An enduring COVID mystery: Why some do fine and others die

The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

By Alexandra Pecci • Jan. 17, 2024

Pharma takes a gut check of microbiome drugs

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

By Kelly Bilodeau • Jan. 16, 2024

4 big FDA approval dates to watch in 2024

Following a year where the FDA approved 55 new drugs, the 2024 PDUFA calendar is set with a number of potentially buzzy approvals. 

By Alexandra Pecci • Jan. 12, 2024

Pharma execs sound off on trends and policies they’re tracking in 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

By Meagan Parrish • Jan. 12, 2024

PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials

As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

By Meagan Parrish • Jan. 11, 2024

Believe the hype? Mixed signals from AI’s impact on drug development

Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.

By Kelly Bilodeau • Jan. 10, 2024

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.

By Meagan Parrish • Jan. 9, 2024

How J&J is tackling a ‘secondary pandemic’ in the Black community

J&J is leading a grassroots effort to improve mental health access and care.

By Alexandra Pecci • Jan. 8, 2024

Regulatory twists and turns are coming for biopharma in 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

By Kelly Bilodeau • Jan. 8, 2024

In the post-pandemic era, three players still dominate the infectious disease market

While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.

By Alexandra Pecci • Jan. 5, 2024

Pharma’s financial market will be a tale of two cities in 2024

What can the industry expect in 2024? Some bright spots, a few bumps and “immaculate disinflation.”

By Kelly Bilodeau • Jan. 4, 2024

Alzheimer’s research is hot, but successful patient recruitment will determine its future

Key strategies for bringing more patients into the clinical trial fold.

By Kelly Bilodeau • Jan. 4, 2024

Why J&J rebranded its iconic logo

J&J’s refreshed identity provides insight into how and why pharma companies give themselves a makeover.

By Alexandra Pecci • Jan. 3, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

Biopharma’s FTC headache deepens with guideline shifts years in the making

Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.

By Michael Gibney • Dec. 21, 2023

What are pharma’s next blockbusters?

In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

By Kelly Bilodeau • Dec. 20, 2023

5 noteworthy pharma AI investments in 2023

The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

By Alexandra Pecci • Dec. 19, 2023

Trends shaping the pharmaceutical industry in 2024

Advancements in cloud and AI technology will transform clinical trial efficiency and engagement.

By Seema Verma, SVP and GM, Oracle Life Sciences • Dec. 18, 2023

Study suggests PBMs are gaming pharmacy system to overcharge for drugs

Markups for generics can be as high as 7,000%, the researchers said.

By Alexandra Pecci • Dec. 15, 2023